Platelet derived growth factor‐BB levels in gingival crevicular fluid of localized intrabony defect sites treated with platelet rich fibrin membrane or collagen membrane containing recombinant human platelet derived growth factor‐BB: A randomized clinical and biochemical study

Background Development of autologous and recombinant growth factor/matrix combination products represent a new emerging trend in regenerative therapeutics and have gained increasing attention as a strategy to optimize tissue regeneration. The aim of the present study was to evaluate the levels of platelet derived growth factor‐BB (PDGF‐BB) in gingival crevicular fluid (GCF) during early healing period after the regenerative treatment of intrabony defects using beta tricalcium phosphate (β‐TCP) as a bone regeneration material with either platelet rich fibrin (PRF) membrane or collagen membrane (CM) treated with recombinant human PDGF‐BB (rhPDGF‐BB). Methods Twenty patients (13 males and 7 females) with chronic periodontitis participated in this prospective, randomized clinical and biochemical study. Each patient was randomly assigned to PRF membrane (group A) or CM incorporated with rhPDGF‐BB (group B). GCF samples were obtained on days 3, 7, 14, and 30 for evaluation of PDGF‐BB levels and alkaline phosphatase (ALP) levels. Results On days 3 and 7 following surgery, mean levels of PDGF‐BB at sites treated with PRF membrane or CM incorporated with rhPDGF‐BB as a barrier membrane were not significantly different. PDGF‐BB levels decreased significantly in samples collected on days 14 and 30 with significant differences between both the groups. ALP levels significantly increased from day 3 to day 30 but there was no difference between two groups. Conclusion Within the limitations of the study, both PRF membrane and CM incorporated with rhPDGF‐BB showed comparable GCF levels of PDGF‐BB initially with PRF showing more sustained levels throughout the study period.